- Home
- TS vs INCY Comparison
TS vs INCY Comparison
Compare TS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TS
- INCY
- Stock Information
- Founded
- TS 2001
- INCY 1991
- Country
- TS Luxembourg
- INCY United States
- Employees
- TS N/A
- INCY N/A
- Industry
- TS Steel/Iron Ore
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- TS Industrials
- INCY Health Care
- Exchange
- TS Nasdaq
- INCY Nasdaq
- Market Cap
- TS 18.4B
- INCY 17.0B
- IPO Year
- TS N/A
- INCY 1993
- Fundamental
- Price
- TS $35.73
- INCY $84.69
- Analyst Decision
- TS Buy
- INCY Buy
- Analyst Count
- TS 5
- INCY 19
- Target Price
- TS $41.80
- INCY $81.73
- AVG Volume (30 Days)
- TS 1.7M
- INCY 1.7M
- Earning Date
- TS 10-29-2025
- INCY 10-28-2025
- Dividend Yield
- TS 4.64%
- INCY N/A
- EPS Growth
- TS N/A
- INCY 900.04
- EPS
- TS 1.84
- INCY 4.37
- Revenue
- TS $11,768,597,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- TS N/A
- INCY $16.41
- Revenue Next Year
- TS $0.75
- INCY $10.86
- P/E Ratio
- TS $9.31
- INCY $19.40
- Revenue Growth
- TS N/A
- INCY 18.87
- 52 Week Low
- TS $30.06
- INCY $53.56
- 52 Week High
- TS $40.87
- INCY $88.66
- Technical
- Relative Strength Index (RSI)
- TS 49.33
- INCY 50.51
- Support Level
- TS $36.11
- INCY $85.18
- Resistance Level
- TS $36.61
- INCY $88.27
- Average True Range (ATR)
- TS 0.59
- INCY 1.93
- MACD
- TS 0.08
- INCY -0.17
- Stochastic Oscillator
- TS 52.96
- INCY 46.75
About TS Tenaris S.A.
Tenaris is one of the largest global producers of oil country tubular goods, which are used primarily in the construction of oil and gas wells. Its production facilities are located primarily in the US, Argentina, Mexico, and Italy. Tenaris' premium OCTG products are among the most trusted by oil companies for use in the most challenging applications, including deep-water offshore wells and horizontal shale wells.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.